# Spero Therapeutics, Inc. (SPRO) · Edgar & Edgarette company card

> Spero Therapeutics (SPRO) grew revenue 39.2% in FY2025 to $67 million, operating margin 9.5% against a -3.8% median for pharmaceutical preparations, equity 85.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1701108 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/SPRO) · [JSON](https://www.pops4.com/boards/company/SPRO.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $67M |
| Revenue growth, 1 year | 39.2% |
| Revenue growth per year | 38.3% |
| Operating margin | 9.5% (prior year -152.9%) |
| Net margin | 12.8% |
| Operating cash flow | −$13M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $40M |
| Long-term debt | — |
| Total assets | $69M |
| Total equity | $59M |
| Equity ÷ assets | 85.6% |
| Return on equity | 14.5% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -8.9 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative; revenue is hard to predict: its 80% range is ±86%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $66.8M (FY2025). Experience: revenue up 39.2% on the year, up 38.3% a year over 4 years; operating margin 9.5%, up from -152.9%. Soundness: equity 85.6% of assets, return on equity 14.5%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $21.2M and $281.0M next year (method v4.1: its own 6-year record of growth weighed at 63% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $23.4M to $256.7M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 9.5% against a -3.8% median; growth 39.2% against 13.7%.

Range logged 2026-09-27, receipt ad2e70cad3867e33, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-10-27 ([filing](https://www.sec.gov/Archives/edgar/data/1701108/000119312526434452/0001193125-26-434452-index.htm))

## Recent filings

- 8-K · filed 2026-10-27 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1701108/000119312526434452/0001193125-26-434452-index.htm)
- 8-K · filed 2026-08-28 · 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1701108/000119312526374788/0001193125-26-374788-index.htm)
- 8-K · filed 2026-08-12 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1701108/000119312526346855/0001193125-26-346855-index.htm)
- 10-Q · filed 2026-08-12 · [filing](https://www.sec.gov/Archives/edgar/data/1701108/000119312526346795/0001193125-26-346795-index.htm)
- 8-K · filed 2026-07-14 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1701108/000119312526302473/0001193125-26-302473-index.htm)
- 8-K · filed 2026-06-25 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1701108/000119312526283033/0001193125-26-283033-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001701108.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1701108

## Cite

POPS4, Edgar & Edgarette: Spero Therapeutics, Inc. (SPRO) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/SPRO. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.